Skip to main content
Unchecking box will stop auto data updates
TSX Real-Time Last Sale CAD
Today's Change
Price Quote as of

Today's Trading

Day Low 2.26
Day High 2.38
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Average Volume
Price/Earnings (TTM)
Trailing Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Resverlogix Corp is a clinical stage biotechnology company. It is engaged in developing RVX-208, a molecule selective inhibit BET domain inhibitor for the treatment of patients with cardiovascular, diabetes mellitus, Alzheimer's & chronic kidney disease.


Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio


Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

Resverlogix Announces Upcoming Presentations at Clinical Trials in Alzheimer's Disease (CTAD) Asia and Alzheimer's Association International Conference (AAIC)
GlobeNewswire - Tue Jul 17, 6:00AM CDT
GlobeNewswire - CMTX
Tue Jul 17, 6:00AM CDT
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has been awarded two presentations at the Clinical Trials in Alzheimer's Disease (CTAD) Asia conference in Shanghai, China. Dr. Jeffrey Cummings, Founding Director of the Cleveland Clinic Lou Ruvo Brain Health Center at Las Vegas, will present an oral communication titled, "Cognitive Evaluation of Treatment Effects of the Bromodomain and Extra-terminal Inhibitor Apabetalone; Design and Baseline Data of the Cognition Substudy of the BETonMACE Phase 3 Cardiovascular Trial" which will highlight the design and baseline characteristics of a prespecified substudy of cognition in elderly patients in the Company's ongoing phase 3 BETonMACE clinical trial. Cognition is being assessed using the Montreal Cognition Assessment (MoCA) in patients 70 years and older at baseline, one-year, two-year and at end of study. In addition, Dr. Cummings will present a poster titled, "Effect of the BET Protein Inhibitor Apabetalone on Serum Markers of Potential Importance for Cognitive Decline in Cardiovascular Disease Patients," illustrating new data from the proteomic analysis from the Company's phase 2 ASSURE clinical trial. The poster will highlight data on proteins that are linked to cognitive decline and neurodegenerative disease and may contribute to neuroplasticity, blood-brain barrier integrity and mitochondrial function. The Company will also highlight the design of the cognition substudy in BETonMACE at a poster presentation at the Alzheimer's Association International Conference (AAIC) in Chicago, USA.
Hemostemix Formalizes World-Class Scientific Advisory Board
GlobeNewswire - Thu Jul 5, 7:29AM CDT
GlobeNewswire - CMTX
Thu Jul 5, 7:29AM CDT
Hemostemix Inc. ("Hemostemix" or the "Company") (TSX-V:HEM) is pleased to announce the formalization of its Scientific Advisory Board ("SAB"). Members of the SAB are all leaders in their fields of expertise, which span biochemistry, molecular biology, genomics and medicine. The mandate of the Scientific Advisory Board will be to serve as a strategic resource for Hemostemix to advise on research and development initiatives surrounding its stem cell technology product pipeline and the furtherance of Hemostemix's clinical pipeline and support the Company's overall mission. Members of the SAB are:
Resverlogix Announces FDA Confirmation Regarding Filing Pathway for Apabetalone
GlobeNewswire - Thu Jun 14, 2:19PM CDT
GlobeNewswire - CMTX
Thu Jun 14, 2:19PM CDT
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has received confirmation from the U.S. Food and Drug Administration ("FDA") that BETonMACE, Resverlogix's on-going Phase 3 study, if successful, is likely to support the filing and approval of a New Drug Application ("NDA"). The statistical analysis plan and endpoints proposed by the Company were reviewed and accepted by the Division of Cardiovascular and Renal Products ("DcaRP") of the FDA. The exact indication to be sought by the Company, and to be reviewed by the FDA, would be driven by the study's results.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 2.00 +14.00% increase
on 06/21/18
Period Open:2.43
Price movement based on the high, low and last over the given period.
2.75 -17.09% decrease
on 06/19/18
-0.15 (-6.17%) decrease
since 06/18/18
3-Month 1.11 +105.41% increase
on 05/31/18
Period Open:1.32
Price movement based on the high, low and last over the given period.
2.75 -17.09% decrease
on 06/19/18
+0.96 (+72.73%) increase
since 04/18/18
52-Week 1.11 +105.41% increase
on 05/31/18
Period Open:1.31
Price movement based on the high, low and last over the given period.
2.75 -17.09% decrease
on 06/19/18
+0.97 (+74.05%) increase
since 07/18/17

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2018.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

More stories below advertisement